Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial

Cervical Intraepithelial Neoplasia Clinical Trial

— ScreenUrSelf  

Official title:

Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05996783
• Other study ID #: B3002023000026
• Status: Recruiting
• Phase: N/A
• Start date: May 25, 2023
• Est. completion date: September 30, 2026

Study information

• Verified date: August 2023
• Source: Universiteit Antwerpen
• Contact: Severien Van Keer, MSc, PhD
• Phone: 03 265 41 92
• Email: severien.vankeer[@]uantwerpen.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the ScreenUrSelf trial is to increase cervical cancer screening attendance and compliance to follow-up by offering a first-void urine self-sampling alternative to women who are currently not participating in the organized cervical cancer screening program (defined in this project as un(der)-screened women), either on the woman or her physician's personal initiative, or by responding on the invitation letter.

Description:

Patient: In this population-based study we target real un(der)-screened women, i.e., women (31-64y) eligible for the Flemish population-based cervical cancer screening program without any cytology/histology/pathological result retrieved from the Belgian Cancer Registry (BCR) for at least the last six years (i.e., two screening rounds). Women who opted out of the screening program, who are pregnant (self-reported), underwent total hysterectomy, have (had) cervical or uterine cancer, or are included in other Centre for Cancer Detection (CvKO) pilot projects are not eligible.

Intervention: The proposed randomized controlled trial (RCT) will be embedded in the Flemish organized cervical cancer screening program, which is coordinated by CvKO under governance of the Flemish government. The goal is to reach women who are eligible but do not participate in cervical cancer screening, by offering two self-sampling methods (first-void urine and vaginal) in an opt-in and -out strategy (total of four interventions) to collect samples for primary high-risk (hr) Human Papillomavirus (HPV) testing, and if positive, reflex 1) cytology on a Pap smear (standard of care) and 2) methylation marker triage (index test).

Comparison: The two control arms include 1) no intervention; and 2) sending (recall) invitation letters to women, inviting them to make an appointment for a Pap smear (i.e., current practise within the organized cervical cancer screening program in Flanders).

Primary outcome: The primary outcome is the actual response rate, i.e., proportions of women that participate in each intervention and in the control arms at 12 months after initiation of the intervention (the intervention being one of six study arms). Response in this project is defined as having a preventive cervical screen exam, either by a self-sample or by a physician-taken Pap smear, at 12 months after initiation of the intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48000
• Est. completion date: September 30, 2026
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 31 Years to 64 Years

Eligibility

Inclusion Criteria:

• Eligible for cervical cancer screening within the organized Population-based Screening Program in Flanders:

• Female

• Residing in Flanders, Belgium

• Not actively opted out of the organized cervical cancer screening program

• No history of total hysterectomy (data available since 2002)

• No (former) diagnosis of cervical or uterine cancer (data available as of 2008)

• Not included in other CvKO pilot projects

• No cervical result registered in the cytohistopathological register of BCR and no information in the administrative data from health insurance companies (IMA) on PAP smears taken for at least the last 6 years (i.e., two screening rounds)

• 31-64 years old (birth year 1959-1992)

Exclusion Criteria:

• Being pregnant or 6 weeks postpartum (self-reported after receiving the study letter/package)

• Participation during menstruation or within the 3 following days is a contraindication

• Not able to understand the study materials and participation form (informed consent form)

Related Conditions & MeSH terms

• Cervical Intraepithelial Neoplasia
• Cervix Cancer
• HPV-Related Cervical Carcinoma
• Human Papilloma Virus
• Papilloma
• Uterine Cervical Dysplasia
• Uterine Cervical Neoplasms

Intervention

Device:
• Colli-Pee Small Volumes
Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
• Evalyn Brush
Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Locations

Country	Name	City	State
Belgium	Universiteit Antwerpen	Edegem	Antwerp

Sponsors (4)

Lead Sponsor	Collaborator
Universiteit Antwerpen	Antwerp University Hospital (UZA), Centre for Cancer Detection (CvKO), Sciensano

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate	Proportions of women that participate in each intervention (measured by PP* and ITT*) and in the control arms (measured by Pap smears taken) within 10 months after the intervention.; *PP: participation in intervention arm measured by self-sample analyses only; **ITT: participation in intervention arm measured by self-sample analyses or Pap smears taken	10 months (until 31/03/2024)
Secondary	Compliance	Compliance to a hrHPV positive result on a self-sample measured by standard of care follow-up, i.e., a Pap smear taken by a clinician.; Compliance to an abnormal Pap smear measured by standard of care follow-up.	19 months (until 31/12/2024)
Secondary	Preference	Preference and attitudes of women between intervention arms (measured via a questionnaire)	Through study completion, an average of 1 year
Secondary	Age-related differences in response rate	Age-related differences in response rates within and between different study arms; Response rates: Proportions of women that participate in each intervention (measured by PP* and ITT*) and in the control arms (measured by Pap smears taken) within 10 months after the intervention.; *PP: participation in intervention arm measured by self-sample analyses only; **ITT: participation in intervention arm measured by self-sample analyses or Pap smears taken	10 months (until 31/03/2024)
Secondary	Socio-economic status-related differences differences in response rate	Socio-economic status-related differences in response rates within and between different study arms; Response rates: Proportions of women that participate in each intervention (measured by PP* and ITT*) and in the control arms (measured by Pap smears taken) within 10 months after the intervention.; *PP: participation in intervention arm measured by self-sample analyses only; **ITT: participation in intervention arm measured by self-sample analyses or Pap smears taken	10 months (until 31/03/2024)
Secondary	Clinical accuracy of HPV assay	Test-positivity, positive predictive value, referral rate to colposcopy, and detection rate of CIN2+ of a hrHPV positive result on a self-sample in un(der)-screened women; absolute measures in each arm and ratios of measures between arms.; Test-positivity, positive predictive value, referral rate to colposcopy, and detection rate of CIN2+ will be combined to report clinical accuracy.	Through study completion, an average of 1 year
Secondary	Clinical accuracy of methylation assay	Test-positivity, positive predictive value, referral rate to colposcopy, and detection rate CIN2+ of a methylation-based reflex test (index test) to triage hrHPV positive self-sample in un(der)screened women, compared to reflex cytology on a Pap smear (comparator test); absolute measures in each arm and ratios of measures between arms.; Test-positivity, positive predictive value, referral rate to colposcopy, and detection rate of CIN2+ will be combined to report clinical accuracy.	Through study completion, an average of 1 year
Secondary	Cost-effectiveness	Differences in time needed per women to obtain a test result between study arms; Differences in costs per women between the different study arms; Differences in total cost between the different study arms; The above differences in time and costs will be combined to report cost-effectiveness.	Through study completion, an average of 1 year